Human brain natriuretic peptide reduces blood pressure in normotensive and acute norepinephrine-induced hypertensive rabbits

American Journal of Hypertension

Volumn 10, Issue 6, 1997, Pages 654-661

  Clemens, L Edward ^a   Almirez, Ramona G ^a   Baudouin, Karine A ^a   Grossbard, Elliott B ^a   Protter, Andrew A ^a  

^a SCIOS INC   (United States)

Author keywords

Atrial natriuretic peptide; Brain natriuretic peptide; Diuresis; Heart failure; Hypertension; Natriuresis

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; NORADRENALIN;

ANIMAL EXPERIMENT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; DRUG EFFECT; HEMODYNAMIC MONITORING; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT;

ANIMALS; BLOOD PRESSURE; DOGS; HUMANS; HYPERTENSION, RENOVASCULAR; NATRIURETIC PEPTIDE, BRAIN; NERVE TISSUE PROTEINS; NOREPINEPHRINE; RABBITS; RATS;

EID: 0030871341     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(97)00048-4     Document Type: Article

References (37)

1. Lewicki JA, Protter AA. Physiological Studies of the Natriuretic Peptide Family. Laragh JH, Brenner BM. Hyertension: Pathophysiology, Diagnosis and Management. 1995;1029-1053 Raven Press, New York.
2. Bennett BD, Bennett GL, Vitangcol RV, et al. Extracellular domain-IgG fusion proteins for three human natriuretic peptide receptors. Hormone pharmacology and application to solid phase screening of synthetic peptide antisera. J Biol Chem. 166:1991;23060-23067.
3. Lowe DG, Fendly BM. Human natriuretic peptide receptor-A guanylyl cyclase. Hormone cross-linking and antibody reactivity distinguish receptor glycoforms. J Biol Chem. 267:1992;21691-21697.
4. Clavell AL, Stingo AJ, Aarhus LL, Burnett J Jr. Biological actions of brain natriuretic peptide in thoracic inferior venacaval constriction. Am J Physiol. 265:1993;R1416-1422.
5. Seymour AA, Asaad MM, Abboa-Offei BE, et al. Potentiation of brain natriuretic peptides by SQ 28,603, an inhibitor of neutral endopeptidase 3.4.24.11, in monkeys and rats. J Pharmacol Exp Ther. 262:1992;60-70.
6. Holmes SJ, Espiner EA, Richards AM, et al. Renal, endocrine, and hemodynamic effects of human brain natriuretic peptide in normal man. J Clin Endocrinol Metab. 76:1993;91-96.
7. Koller KJ, Goeddel DV. Molecular biology of the natriuretic peptides and their receptors. Circulation. 86:1992;1081-1088.
8. Schoenfeld JR, Sehl P, Quan C, et al. Agonist selectivity for three species of natriuretic peptide receptor-A. Mol Pharmacol. 47:1995;172-180.
9. Furuya M, Ohnuma N, Takehisa M, et al. Pharmacological activities of brain natriuretic peptides of human, porcine and rat origin. Eur J Pharmacol. 200:1991;233-237.
10. Kambayashi Y, Nakao K, Kimura H, et al. Biological characterization of human brain natriuretic peptide (BNP) and rat BNP: species-specific actions of BNP. Biochem Biophys Res Commun. 173:1990;599-605.
11. Yoshimura M, Yasue H, Morita E, et al. Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Circulation. 84:1991;1581-1588.
12. Abraham WT, Lowes BD, Ferguson DA, et al. Systemic hemodynamic and renal excretory effects of a continuous 4-hour infusion of human brain natriuretic peptide in patients with heart failure (abst). J Am Coll Cardiol. 25:1995;236A.
13. Marcus LS, Hart D, Packer M, et al. Hemodynamic and renal effects of brain natriuretic peptide infusion in patients with congestive heart failure: a double-blind, placebo-controlled, randomized crossover trial. Circulation. 94:1996;3184-3189.
14. Hobbs RE, Miller LW, Bott-Silverman C, et al. Hemodynamic effects of a single intravenous injection of synthetic human brain natriuretic peptide in patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 78:1996;896-901.
15. Roberts AJ, Niarchos AP, Subramanian VA, et al. Systemic hypertension associated with coronary artery bypass surgery. Predisposing factors, hemodynamic characteristics, humoral profile, and treatment. J Thorac Cardiovasc Surg. 74:1977;846-859.
16. Wallach R, Karp RB, Reves JG, et al. Pathogenesis of paroxysmal hypertension developing during and after coronary bypass surgery: a study of hemodynamic and humoral factors. Am J Cardiol. 46:1980;559-565.
17. Reves JG, Karp RB, Buttner EE, et al. Neuronal and adrenomedullary catecholamine release in response to cardiopulmonary bypass in man. Circulation. 66:1982;49-55.
18. Engelman RM, Haag B, Lemeshow S, et al. Mechanism of plasma catecholamine increases during coronary artery bypass and valve procedures. J Thorac Cardiovasc Surg. 86:1983;608-615.
19. Gray RJ, Bateman TM, Czer LS, et al. Comparison of esmolol and nitroprusside for acute post-cardiac surgical hypertension. Am J Cardiol. 59:1987;887-891.
20. Protter AA, Wallace AM, Ferraris VA, Weishaar RE. Relaxant effect of human brain natriuretic peptide on human artery and vein tissue. Am J Hypertens. 9:1996;432-436.
21. Florkowski CM, Richards AM, Espiner EA, et al. Renal, endocrine, and hemodynamic interactions of atrial and brain natriuretic peptides in normal men. Am J Physiol. 266:1994;R1244-1250.
22. Kato H, Yasue H, Yoshimura M, et al. Suppression of hyperventilation-induced attacks with infusion of B-type (brain) natriuretic peptide in patients with variant angina. Am Heart J. 128:1994;1098-1104.
23. Richards AM, Crozier IG, Holmes SJ, et al. Brain natriuretic peptide: natriuretic and endocrine effects in essential hypertension. J Hypertens. 11:1993;163-170.
24. Camargo MJ, Atlas SA, Maack T. Role of increased glomerular filtration rate in atrial natriuretic factor-induced natriuresis in the rat. Life Sci. 38:1986;2397-2404.
25. Sosa RE, Volpe M, Marion DN, et al. Relationship between renal hemodynamic and natriuretic effects of atrial natriuretic factor. Am J Physiol. 250:1986;F520-524.
26. Cogan MG. Atrial natriuretic factor can increase renal solute excretion primarily by raising glomerular filtration. Am J Physiol. 250:1986;F710-714.
27. Seymour AA, Smith S, Mazack EK. Effects of renal perfusion pressure on the natriuresis induced by atrial natriuretic factor. Am J Physiol. 253:1987;F234-238.
28. Gilman AG, Goodman LS, Rall TW, Murad F. The Pharmacological Basis of Therapeutics. Seventh Edition :1985;Macmillan, New York.
29. La Villa G, Bisi G, Lazzeri C, et al. Cardiovascular effects of brain natriuretic peptide in essential hypertension. Hypertension. 25:1995;1053-1057.
30. Lappe RW, Todt JA, Wendt RL. Hemodynamic effects of infusion versus bolus administration of atrial natriuretic factor. Hypertension. 8:1986;866-873.
31. Almeida FA, Suzuki M, Maack T. Atrial natriuretic factor increases hematocrit and decreases plasma volume in nephrectomized rats. Life Sci. 39:1986;1193-1199.
32. Chien YW, Frohlich ED, Trippodo NC. Atrial natriuretic peptide increases resistance to venous return in rats. Am J Physiol. 252:1987;H894-H899.
33. Yasujima M, Abe K, Kohzuki M, et al. Atrial natriuretic factor inhibits the hypertension induced by chronic infusion of norepinephrine in conscious rats. Circ Res. 57:1985;470-474.
34. Parkes DG, Coghlan JP, McDougall JG, Scoggins BA. Effects of atrial natriuretic factor on pressor responsiveness to angiotensin II, norepinephrine, and vasopressin in conscious sheep. J Cardiovasc Pharmacol. 15:1990;16-21.
35. Uehlinger DE, Weidmann P, Gnaedinger MP, et al. Depressor effects and release of atrial natriuretic peptide during norepinephrine or angiotensin II infusion in man. J Clin Endocrinol Metab. 63:1986;669-674.
36. Hanford DS, Thuerauf DJ, Murray SF, Glembotski CC. Brain natriuretic peptide is induced by alpha 1-adrenergic agonists as a primary response gene in cultured rat cardiac myocytes. J Biol Chem. 269:1994;26227-26233.
37. Suga S, Nakao K, Hosoda K, et al. Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide. Endocrinology. 130:1992;229-239.